Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome

Current Opinion in Investigational Drugs

Volumn 8, Issue 7, 2007, Pages 570-579

  Chazot, P L ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPA RECEPTOR ANTAGONIST; DOPAMINE; GABAPENTIN; GANGLIOSIDE GM1; HARKOSERIDE; ICA 27243; KAINIC ACID; LAMOTRIGINE; LEVODOPA; NEURITE PROMOTING FACTOR; NEUROIMMUNOPHILIN; NS 1209; OXIDOPAMINE; POTASSIUM CHANNEL STIMULATING AGENT; RETIGABINE; SAFINAMIDE; SELEGILINE; TALAMPANEL; UBIDECARENONE; UNCLASSIFIED DRUG;

ABNORMAL THINKING; AFTERDISCHARGE; AMNESIA; ATAXIA; CELL MEMBRANE DEPOLARIZATION; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOPAMINE BRAIN LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; HUMAN; IC 50; INTRACTABLE EPILEPSY; NEUROPROTECTION; NONHUMAN; PAIN; PARKINSON DISEASE; PUTAMEN; RECEPTOR AFFINITY; REPEATED DRUG DOSE; RESTLESS LEGS SYNDROME; REVIEW; SOMNOLENCE; SPEECH DISORDER; STRUCTURE ACTIVITY RELATION; THERAPY EFFECT; TONIC CLONIC SEIZURE; TOXICITY TESTING; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VERTIGO;

ALANINE; ANIMALS; BENZYLAMINES; CLINICAL TRIALS; EPILEPSY; HUMANS; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; RESTLESS LEGS SYNDROME;

EID: 34347340522     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. 179853 The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. Strolin Benedetti MS, Marrari P, Colombo M, Castelli MG, Arand M, Oesch F, Dostert P J PHARM PHARMACOL 1994 46 10 814-819
2. 229912 Anticonvulsant profile of FCE26743A, a novel 2-amino-propionamide derivative. Salveti P, Algate C, Beard D, Bonsignori A, Cervini MA, McArthur RA, Maj R, Pevarello P, Varasi M, Fariello R, Post C ABSTR SOC NEUROSCI 1996 22 3 2109
3. 279845 Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl)amino]alkanamide derivatives. Pevarello P, Bonsignori A, Dostert P, Heidempergher F, Pinciroli V, Colombo M, McArthur RA, Salvati P, Post C, Fariello RG, Varasi M J MED CHEM 1998 41 4 579-590
4. 288997 Preclinical evaluation of PNU-151774E as a novel anticonvulsant. Fariello RG, McArthur RA, Bonsignori A, Cervini MA, Maj R, Marrari P, Pevarello P, Wolf HH, Woodhead JW, White HS, Varasi M et al J PHARMACOL EXP THER 1998 285 2 397-403
5. 308267 PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Maj R, Fariello RG, Ukmar G, Varasi M, Pevarello P, McArthur RA, Salvati P EUR J PHARMACOL 1998 359 1 27-32
6. 340887 Sodium channel activity and sigma binding of 2-amino-propanamide anticonvulsants. Pevarello P, Bonsignori A, Caccia C, Amici R, McArthur RA, Fariello R, Salvati P, Varasi M BIOORG MED CHEM LETT 1999 9 17 2521-2525
7. 345222 PNU-15177AE, a combined MAO-B and glutamate release inhibitor, is effective in animal models of Parkinson's disease. Mai R, Calabresi M, Caccia C, Salvati P, Fariello RG ABSTR SOC NEUROSCI 1999 25 2 Abs 640.16
8. 348351 Drug development pipeline: Newron. Newron Pharmaceuticals SpA COMPANY COMMUNICATION 1999 November 15
9. 373379 New anti-epileptic drugs - fifth Eilat conference (Part A), Eilat, Israel 25-29 June 2000. Perucca E IDDB MEETING REPORT 2000 June 25-29
10. 373763 Acute behavioral and EEG effects of NW-1015 on electrically-induced afterdischarge in conscious monkeys. Fariello RG, Maj R, Marrari P, Beard D, Algate C, Salvati P EPILEPSY RES 2000 39 1 37-46
11. 373764 Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures. Maj R, Fariello RG, Pevarello P, Varasi M, McArthur RA, Salvati P EPILEPSIA 1999 40 11 1523-1528
12. 373766 Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. Salvati P, Maj R, Caccia C, Cervini MA, Fornaretto MG, Lamberti E, Pevarello P, Skeen GA, White HS, Wolf HH, Faravelli L J PHARMACOL EXP THER 1999 288 3 1151-1159
13. 373771 Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. Strolin Benedetti M, Tocchetti P, Rocchetti M, Martignoni M, Marrari P, Poggesi I, Dostert P PROG BRAIN RES 1995 106 4 123-134
14. 395700 Effects of co-administration of anticonvulsant and putative anticonvulsant agents and sub/suprathreshold doses of L-dopa upon motor behavior of MPTP-treated mice. Fredriksson A, Palomo T, Archer T J NEURAL TRANSM 1999 106 9-10 889-909
15. 403425 Drug development pipeline - safinamide. Newron Pharmaceuticals COMPANY COMMUNICATION 2001 January 26
16. 410623 An important industrial initiative supported by international venture capital specialists. Newron Pharmaceuticals SpA PRESS RELEASE 1999 October 06
17. 428392 Characterization of MAO-B inhibitory of safinamide (NW-105) in animals and healthy volunteers. Caccia CP, Musanti R, Calabresi M, Tocchetti P, Del Bo L, Fariello RG, Benatti L, Salvati P ABSTR SOC NEUROSCI 2001 27 14 Abs 862.16
18. 491110 New drug candidate for Parkinson's. Fariello R SMI CONF - NEURODEGENERATIVE DISORDERS 2003 May 21-22
19. 557481 Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Marzo A, Dal Bo L, Ceppi Monti N, Crivelli F, Ismaili S, Caccia C, Cattaneo C, Fariello RG PHARMACOL RES 2004 50 1 77-85
20. 558666 Newron's safinamide enters pivotal phase III study for PD. Newron Pharmaceuticals SpA PRESS RELEASE 2004 September 13
21. 563871 Dynogen obtains rights to Newron's ion channel modulators. Dynogen Pharmaceuticals Inc PRESS RELEASE 2004 October 12
22. 579123 Newron's safinamide reduces restless legs symptoms in phase II trial. Newron Pharmaceuticals SpA PRESS RELEASE 2005 January 11
23. 651125 Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Cattaneo C, Caccia C, Marzo A, Maj R, Fariello RG CLIN NEUROPHARMACOL 2003 26 4 213-217
24. 674506 Newron's safinamide improves UPDRS scores in phase III Parkinson's trial. Newron Pharmaceuticals SpA PRESS RELEASE 2006 June 19
25. 693810 Improvement of motor function in early Parkinson disease by safinamide. Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Bonuccelli U, Van Dijk A, Cattaneo C, Sala P, Fariello RG NEUROLOGY 2004 63 4 746-748
26. 693811 Motor improvement in early Parkinson disease under treatment with safinamide, a new neuroprotectant. Results from a parallel double blind placebo controlled multinational study. Stocchi F, Onofrj M, Arnold G, Kwiecinski H, Szczudlik A NEUROLOGY 2004 62 7
27. 693815 Motor function: Follow-up in patients affected by Parkinson's disease treated previously with safinamide. Thomas A, Cattaneo C, Besana C, Sala P, Onofrj M, Baratti M, Nordera G, Fabbrini G, Barbanti P, Fariello RG J NEURAL TRANSM 2004 111 5 XLIII
28. 693816 Safinamide add-on to levodopa and dopamine agonist in Parkinson disease. An open escalating dose six week trial. Stocchi F, Vacca L, Grassini P, Battaglia G, Altobrandi MG, Ruggieri S J NEURAL TRANSM 2004 111 5 XLI
29. 693817 A pilot study of safinamide in medically intractable epilepsy. Tolerability, drug-drug interaction and efficacy data. Perucca E, Avanzini G, Onofrj M, Thomas A, Manfredi M, Di BC, Sala P, Cattaneo C J NEURAL TRANSM 2004 111 5 XXIX
30. 731077 Serono licenses Newron's safinamide for cognitive disorders. Serono SA PRESS RELEASE 2006 October 16
31. 739846 Restless legs syndrome: Treatment with dopaminergic agents. Comella CL NEUROLOGY 2002 58 4 Suppl 1 S87-S92
32. 739863 Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score ≥ 24 points ? data from the ropinirole clinical trial programme. Giorgi L, Ritchie SY, Kirsch JM CURR MED RES OPIN 2006 22 10 1867-1877
33. 743027 Pediatric posttraumatic seizures: Epidemiology, putative mechanisms of epileptogenesis and promising investigational progress. Statler KD DEV NEUROSCI 2006 28 4-5 354-363
34. 743030 Seizures and brain tumors. Sperling MR, Ko J SEMIN ONCOL 2006 33 3 333-341
35. 743033 Voltage gated ion channels: Targets for anticonvulsant drugs. Errington AC, Stohr T, Lees G CURR TOP MED CHEM 2005 5 1 15-30
36. 743035 Critical re-evaluation of previous preclinical strategies for the discovery and the development of new antiepileptic drugs. Loscher W, Leppik IE EPILEPSY RES 2002 50 1-2 17-20
37. 743145 New pharmacologic horizons in the treatment of Parkinson disease. Bonuccelli U, Dotto PD NEUROLOGY 2006 67 7 Suppl 2 S30-S38
38. 743147 Diverse mechanisms of antiepileptic drugs in the development pipeline. Rogawski MA EPILEPSY RES 2006 69 3 273-294
39. 743149 Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias. Hauser RA GERIATRICS 2006 61 9 14-20
40. 743157 Transdermal selegiline: The new generation of monoamine oxidase inhibitors. Patkar AA, Pae CU, Masand PS CNS SPECTR 2006 11 5 363-375
41. 743168 Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Loscher W, Schmidt D EPILEPSIA 2006 47 8 1253-1284
42. 743172 Restless legs syndrome probably induced by risperidone treatment. Wetter TC, Brunner J, Bronisch T PHARMACOPSYCHIATRY 2002 35 3 109-111
43. 743177 Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. Riederer P, Youdim MB J NEUROCHEM 1986 46 5 1359-1365
44. 743184 Modulation of brain mitochondrial function by deprenyl. Czerniczyniec A, Bustamante J, Lores-Arnaiz S NEUROCHEM INT 2006 48 3 235-241
45. 743190 Safinamide: From molecular targets to a new anti-parkinson drug. Caccia C, Calabresi M, Maestroni S, Faravelli L, Curatolo Salvati P, Fariello RG NEUROLOGY 2006 67 Suppl S18-S23
46. 743262 Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Stocchi F, Vacca L, Grassini P, De Pandis MF, Battaglia G, Cattaneo C, Fariello RG NEUROLOGY 2006 67 7 Suppl 2 S24-S29
47. 743270 Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease. Chen JJ, Swope DM J CLIN PHARMACOL 2005 45 8 878-894
48. 744992 Clinically relevant drug interactions with antiepileptic drugs. Perucca E BR J CLIN PHARMACOL 2006 61 3 246-255
49. 789895 Phase III data on safinamide in Parkinson's disease presented at American Academy of Neurology 59th Annual Meeting. Merck Serono SA PRESS RELEASE 2007 May 02
50. 790612 Novel anticonvulsant drugs. Stefan H, Feuerstein TJ PHARMACOL THER 2007 113 1 165-183
51. 790613 Safinamide, a new anti-parkinson agent is effective and well-tolerated in early PD patients on a stable dose of a single DA-agonist: Results of a randomized, international, placebo-controlled, phase III trial. Stocchi F, Onofrj M, Shapira A, Bhatt MH, Rossetti S, Lorenzana P ANN MEET AM ACAD NEUROL 2007 59 2 S200.001
52. 796397 End of drug-chemical hybrids? Spengler P, Maul T NATEXIS BLEICHROEDER INC 2006 November 29
53. 796400 Pharma catalyst planner - catalysts, patents and pipelines. Plag S, Dodwell J, Garcia-Sagues U, Gasteyger S, Holford J, Bedford T, Hilliker I, Bardo S CREDIT SUISSE EUROPE 2007 March 27